MedTrace Logo

Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus

NCT05846971 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-05-06

No results posted yet for this study

Summary

Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions when presented with different clinical and prognostic assay information.

Conditions

  • Barrett Esophagus
  • Esophageal Cancer

Interventions

OTHER

Educational materials on validated methylation assay

Educational materials include overall information on the assay including what the test does, how to use the test and report, and performance metrics on the test.

Sponsors & Collaborators

  • Capsulomics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-26
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05846971 on ClinicalTrials.gov